Comprehensive Investor Relations and Media Outreach to Commence
LA JOLLA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) (http://www.transdelpharma.com) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing non-invasive, topically administered medications, has retained the Investor Relations Group ("IRG"), a thirteen-year-old, highly recognized corporate communications firm based in New York City, to serve as its investor relations and public relations firm.
IRG will strive to increase the Company's public exposure and to communicate the advantages of its innovative proprietary transdermal delivery technology, Transdel(TM), its lead topical drug, Ketotransdel(TM) and its other drug candidates through a focused campaign. On the investor relations front, IRG will use its proprietary database of investors to introduce the Company to targeted members of the investment community through pre-qualified one-on-one introductions, e-mails to professionals that have opted-in to receive communication, interviews, and traditional outreach. In the public relations arena, IRG will educate audiences of editors, writers, and segment producers of local and national trade and consumer print, radio, on-line, and broadcast media outlets about the Company and its role in the market.
The Company's lead topical drug, Ketotransdel(TM), utilizes their Transdel(TM) cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other novel and generic drugs and promising therapeutic areas in combination with using their patented transdermal delivery system. Furthermore, the Company is actively pursuing the development of cosmeceutical products.
"With our lead product, Ketotransdel(TM), in Phase 3 clinical trial, and a strong pipeline of co-development opportunities utilizing our Transdel(TM) platform technology, this is an opportune time to increase our visibility within the investment and media community," said Dr. Juliet Singh, President and CEO of Transdel Pharmaceuticals. "As we remain focused on our clinical program and growth objectives, we look forward to IRG communicating our progress to the appropriate target audiences."
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty pharmaceutical company developing non-invasive, topically-delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit http://www.transdelpharma.com.
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at http://www.investorrelationsgroup.com.
Safe Harbor Statement
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
|SOURCE Transdel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved